Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Engineering functionalized nanoparticles for HIV prevention

FY 2018-19

Summary
It has been more than 30 years since the discovery of HIV-1 as the cause of AIDS and so far, there are no vaccines that exists to prevent HIV-1 infection. The challenge in developing an HIV-1 vaccine is that the virus is immensely diverse and can evade our immune system’s responses. Broadly neutralizing antibodies (bNAbs) were recently discovered and individually, bNAbs can neutralize >90% of circulating HIV-1 isolates. Nevertheless, combining different bNAbs together in a single molecule, called bi-specific and tri-specific antibodies, can achieve near 100% neutralization with high potency. This breakthrough discovery has attracted considerable attention as bNAbs hold the promise of helping guide vaccine development, which can be used as a prophylactic against HIV-1. The Julien lab has developed and patented a novel protein-based nanoparticle platform to multimerize antibody fragments that bind to antigens (Fabs). Using the Fab-nanaoparticle technology, I will genetically engineer a functionalized nanoparticle that combines up to 24 different Fab regions of bNAbs in a single antibody prophylactic. The nanoparticle will increase breadth of coverage with high potency to surpass the activity of bi-specific and even tri-specific antibodies. To effectively translate the technology as an injectable prophylactic for HIV-1 prevention pre-clinically, I must assess its half-life, biodistribution, toxicity and immunogenicity. The study involves designing, expressing and purifying a fully mouse-derived functionalized nanoparticle to test in mice. The results of this study will guide the development of a fully human-derived functionalized nanoparticle and this novel approach will transform the field of HIV-1 antibody vaccine development and help end the HIV/AIDS pandemic.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406520
Name
Nouanesengsy Amy
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering functionalized nanoparticles for HIV prevention
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aids; Bi- And Tri-Specific Antibodies; Broadly Neutralizing Antibodies; Hiv-1; Immunology; Infectious Diseases; Nanoparticle; Platform Technology; Protein Engineering; Vaccine
Abstract
It has been more than 30 years since the discovery of HIV-1 as the cause of AIDS and so far, there are no vaccines that exists to prevent HIV-1 infection. The challenge in developing an HIV-1 vaccine is that the virus is immensely diverse and can evade our immune system’s responses. Broadly neutralizing antibodies (bNAbs) were recently discovered and individually, bNAbs can neutralize >90% of circulating HIV-1 isolates. Nevertheless, combining different bNAbs together in a single molecule, called bi-specific and tri-specific antibodies, can achieve near 100% neutralization with high potency. This breakthrough discovery has attracted considerable attention as bNAbs hold the promise of helping guide vaccine development, which can be used as a prophylactic against HIV-1. The Julien lab has developed and patented a novel protein-based nanoparticle platform to multimerize antibody fragments that bind to antigens (Fabs). Using the Fab-nanaoparticle technology, I will genetically engineer a functionalized nanoparticle that combines up to 24 different Fab regions of bNAbs in a single antibody prophylactic. The nanoparticle will increase breadth of coverage with high potency to surpass the activity of bi-specific and even tri-specific antibodies. To effectively translate the technology as an injectable prophylactic for HIV-1 prevention pre-clinically, I must assess its half-life, biodistribution, toxicity and immunogenicity. The study involves designing, expressing and purifying a fully mouse-derived functionalized nanoparticle to test in mice. The results of this study will guide the development of a fully human-derived functionalized nanoparticle and this novel approach will transform the field of HIV-1 antibody vaccine development and help end the HIV/AIDS pandemic.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nouanesengsy, Amy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~